Title Page

Title: Decreased Fentanyl Potency as the Primary Driver of the 2024 Decline in U.S. Overdose Deaths

Author Name: Daniel A. Busch

Institutional Affiliation: Northwestern University Feinberg School of Medicine, Department of Psychiatry and Behavioral Sciences, Chicago, IL, USA

Corresponding Author: Daniel A. Busch, M.D., M.P.H.
Email: dbusch2@uic.edu

Abstract:

Background: Two major hypotheses have been used to explain the unprecedented 26.9% decline in U.S. drug overdose deaths from 2023 to 2024: (1) expanded public health infrastructure and (2) reduced potency of the illicit fentanyl supply. This study was designed to test these competing hypotheses by comparing temporal changes in overdose death rates when fentanyl was present with those when fentanyl was absent.

Methods: Using CDC WONDER mortality data (2018-2024), overdose deaths from each of five non-fentanyl drugs were disaggregated into fentanyl-positive and fentanyl-negative deaths, for which trends over time were then compared. A first analysis involved 2023-2024 rate change ratios calculated separately for fentanyl-positive and fentanyl-negative deaths from each drug. This analysis was repeated for the group of fentanyl-positive and fentanyl-negative deaths. A similar analysis was performed comparing observed 2024 deaths with deaths predicted from 2018-2023 log-linear regressions. The two analyses were repeated for non-fentanyl opioids only.

Results: From 2023 to 2024, fentanyl-positive deaths decreased by 31.7%, while fentanyl-negative deaths increased by 2.6% ($p<0.025$). Observed 2024 deaths from fentanyl-positive drugs fell significantly below predictions ($p<0.005$) derived from regression equations, while fentanyl-negative deaths showed no significant deviation from predictions. Repeat analysis confined to non-fentanyl opioids found similar results.

Conclusions: The 2023-2024 overdose mortality decline was confined to deaths involving fentanyl. These findings support the hypothesis that reduced fentanyl potency, not expanded public health infrastructure, drove the mortality decline. Policy responses should balance supply-side interventions with sustained infrastructure development, while preparing for potential market adaptations toward more potent synthetic opioids.

Title: Decreased Fentanyl Potency as the Primary Driver of the 2024 Decline in U.S. Overdose Deaths

Main Manuscript:

Introduction:

The 27% decline in U.S. drug overdose deaths from 2023 (110,037 deaths) to 2024 (80,391 deaths) constitutes a dramatic reversal of a two-decade upward trend (NCHS, 2025). While welcome, the causes of this sharp decline remain uncertain. Fischer et al. (2025) identified potential drivers of similar declines in Canada across four domains: changes in the at-risk population, drug-supply characteristics, safer-use practices, and treatment access.

Two competing hypotheses have drawn the most attention in the United States.

The "fentanyl hypothesis" attributes the decline primarily to reduced potency or purity of illicit fentanyl (DEA, 2024; Milgram, 2024). DEA data showed that fentanyl potency and purity fell contemporaneously with the decline in overdose deaths (DEA, 2025) (Figure 1).

Figure 1.



Drug Enforcement Administration, 2025.

Figure 1. Fentanyl purity and seizures for pills and powder (DEA)

Dasgupta et al. (2025) contested this interpretation, pointing to state-level variation in the timing of overdose declines and raising concerns about the DEA purity data. Their interpretation aligned with the "infrastructure hypothesis," which attributes national declines to the expansion of prevention, harm-reduction, treatment, and recovery systems.

A CDC report stated that the decline in deaths was due to multiple factors but did not attempt to differentiate the relative contributions of infrastructure development and decreased fentanyl potency (CDC, 2025a).

CDC findings (CDC, 2025a; Anderer et al., 2025) showed declines not only in fentanyl-involved deaths but also in deaths involving five non-fentanyl drugs: cocaine, methamphetamine, prescription opioids, heroin, and methadone. This broad decrease casts doubt on the fentanyl hypothesis, which would predict declines only in deaths involving fentanyl.



Figure 2. Percent change in total overdose deaths by drug, 2023-2024.

However, it is important to note that the CDC's methodology for classifying overdose deaths assigns each death to every drug detected in the decedent. Therefore, a cocaine death may also be a fentanyl death. Consequently, a drop in fentanyl purity would decrease cocaine deaths for the subgroup of cocaine deaths in which fentanyl was also present.

The present analysis separates deaths from cocaine, methamphetamine, prescription opioids, heroin, and methadone into two groups: those in which fentanyl is also present ("fentanyl-positive") and those in which it is not ("fentanyl-negative"). If infrastructure improvements drove the national decline, mortality reductions should appear in both groups. Conversely, if changes in fentanyl potency were the dominant factor, reductions should be concentrated in fentanyl-positive deaths, with little to no effect on fentanyl-negative cases.

2. Methods:

2.1. Data Source:

Mortality data were extracted from the CDC WONDER database (CDC, 2025b). 2024 data were provisional at analysis.

2.2. Case Definition:

Cases included all deaths from 2018-2024 with underlying cause of death coded as drug poisoning (ICD-10: X40-X44 [unintentional], X60-X64 [intentional self-harm], X85 [homicidal poisoning], Y10-Y14 [undetermined intent])(WHO, 1992) and involvement of any one or more of the following drugs: T40.1 (heroin), T40.2 (prescription opioids), T40.3 (methadone), T40.4 (fentanyl), T40.5 (cocaine), and T43.6 (methamphetamine) .

2.3. Drug Classification:

Deaths involving fentanyl with no study drugs were classified as "fentanyl-only." The five study drugs were classified as "non-fentanyl drugs." A subset of the non-fentanyl drugs—prescription opioids, heroin, and methadone—were classified as "non-fentanyl opioids." Each death from a non-fentanyl drug was either fentanyl-positive (with fentanyl co-involvement) or fentanyl-negative (without fentanyl).

2.4. Statistical Analysis:

All analyses used $\alpha=0.05$. 2024/2023 death ratios were calculated separately for fentanyl-positive and fentanyl-negative groups of non-fentanyl drugs and non-fentanyl opioids, as well as for each drug individually. Poisson regression with z-tests compared fentanyl-positive and fentanyl-negative results. Log-linear regression models were developed from 2018-2023 overdose death rates to predict 2024 deaths. One-sample One-tailed t-tests were used to assess whether observed 2024 death rates fell below predicted values for each fentanyl-positive and each fentanyl-negative drug, as well as for the groups of non-fentanyl drugs and non-fentanyl opioids. A paired t-test compared differences (observed-predicted) between fentanyl-positive and fentanyl-negative groups of non-fentanyl drugs and non-fentanyl opioids. For display purposes, logs of observed and predicted 2024 death rates were back-converted to numbers of deaths. Power analyses estimated Type II error probabilities for fentanyl-negative drugs.

3. Results:

3.1. 2023-2024 Mortality Changes:

Disaggregating deaths into fentanyl-positive and fentanyl-negative revealed a pattern strikingly different from Figure 1 above. Fentanyl-positive deaths decreased substantially for all five non-fentanyl drugs, while fentanyl-negative deaths *increased* for cocaine, methamphetamine, and methadone. Declines for deaths from fentanyl-negative prescription opioids and heroin were less than declines for fentanyl-positive deaths from those drugs (Figure 3).



Figure 3. Percent change in fentanyl-positive and fentanyl-negative overdose deaths by drug, 2023-2024.

Differences in 2024/2023 overdose mortality ratios for fentanyl-positive and fentanyl-negative cocaine, methamphetamine, prescription opioids, and methadone were each highly significant ($p<.001$); heroin trended in the same direction ($p<.09$).

Aggregated across all five non-fentanyl drugs, fentanyl-positive deaths decreased 31.7%, while fentanyl-negative deaths increased 2.6%. This difference was highly significant ($z=-36.98$, $p<.0001$).

Aggregated across the three non-fentanyl opioids, fentanyl-positive deaths decreased 29.9%, while fentanyl-negative opioid deaths fell 3.7%. This difference was highly significant ($z=-39.66$, $p<.0001$)

3.2. Predicted versus Observed Mortality:

Predictions for 2024 overdose deaths derived from log-linear models based on 2018-2023 data were compared with observed deaths for fentanyl-positive and fentanyl-negative drugs (Figure 4).

Figure 4. Actual overdose deaths for the individual fentanyl-positive and fentanyl-negative drugs compared with deaths predicted by 2018-2023 log-linear regression equations					
	Actual	Predicted	Lower Prediction Limit	p<.05	Actual as % of predicted
4. A. Fentanyl-only	16,072	39,081	21,125	*	41.1
4. B. Fentanyl-positive drugs					
Cocaine	14,396	29,955	23,343	*	48.1
Methamphetamine	16,366	45,202	21,143	*	36.2
Prescription opioids	3,742	7,402	3,993	*	50.6
Heroin	2,208	3,120	1,830		70.8
Methadone	1,694	2,605	1,654		65.0
4. C. Fentanyl-negative drugs					
Cocaine	7,548	7,243	6,036		104.2
Methamphetamine	12,354	13,898	10,096		88.9
Prescription opioids	4,242	3,997	3,781		106.1
Heroin	536	530	272		101.1
Methadone	1,533	1,336	1,062		114.7

Figure 4. Actual versus predicted 2024 overdose deaths for fentanyl-positive and fentanyl-negative drugs.

Observed fentanyl-positive deaths (4.B.) were well below predicted (36.2-70.8%). For cocaine, methamphetamine, and prescription opioids, this difference met criteria for significance. Deaths from fentanyl-positive heroin and methadone trended in the same direction. Fentanyl-negative deaths (4.C.) from all drugs fell close to predicted values (89-115%).

As a group, observed 2024 fentanyl-positive drug deaths (4.B.) were significantly below predicted ($t=-5.40$, $df=4$, $p<0.005$), while for fentanyl-negative drugs (4.C.), observed deaths were close to predicted deaths ($t=0.63$, $df=4$, p=NS). The paired difference between the fentanyl-positive and fentanyl-negative groups was significant ($t=-7.11$, $df=4$, $p<0.001$).

For the group of fentanyl-positive non-fentanyl opioids, observed 2024 deaths fell significantly below predicted deaths ($t=-3.54$, $df=2$, $p<0.05$). For fentanyl-negative opioids, observed deaths were close to predicted deaths ($t=0.68$, $df=2$, p=NS). The paired

difference between the fentanyl-positive and fentanyl-negative opioid groups was significant ($t=-4.98$, $df=2$, $p<0.05$).

3.3. Type II Error Analysis:

The probability of missing true decreases in fentanyl-negative deaths was minimal for cocaine ($\beta<0.01$), prescription opioids ($\beta<0.001$), and methadone ($\beta<0.001$), and higher for heroin ($\beta=0.076$) and methamphetamine ($\beta=0.18$).

4. Discussion:

4.1. Principal Findings:

This study demonstrates that the unprecedented and unexpected decline in U.S. overdose mortality in 2024 was confined to deaths involving fentanyl. Three findings support this conclusion. First, only mortality involving fentanyl-positive drugs decreased; mortality involving fentanyl-negative drugs did not change. Second, only fentanyl-positive deaths fell below values predicted by the 2018–2023 regression model. Third, these patterns persisted when analyses were restricted to non-fentanyl opioid-involved cases.

Collectively, these results indicate that reduced fentanyl potency—rather than improved treatment, prevention, and harm-reduction infrastructure—was the primary driver of the 2024 mortality decline. If the 2024 drop in overdose deaths were significantly attributable to infrastructure development, fentanyl-negative drugs, especially fentanyl-negative opioids, should have participated in the decline. These findings are consistent with DEA reports of declining fentanyl purity (DEA, 2025) and challenge infrastructure-based explanations for the short-term decrease.

4.2. Ancillary Findings:

First, the analysis had high statistical power to detect a change in prescription opioid and methadone deaths. The finding that no meaningful reduction was observed for these drugs—which constituted over 90% of non-fentanyl opioid deaths—strengthens the conclusion that the 2023–2024 mortality decline was specific to fentanyl.

Second, for prescription opioids and heroin specifically, the observed number of deaths in 2024 matched the predicted number. This indicates that the decrease in deaths for these drugs from 2023 to 2024 was consistent with pre-existing, long-term trends and not part of the acute decrease in deaths in 2024.

4.3. Methodological Considerations:

First, One-tailed t-tests were used in the log-linear regression models because the study objective was directional: identifying whether observed deaths for each fentanyl-positive

and fentanyl-negative drug and for the respective drug groups fell below predicted 2024 deaths.

Second, higher Type II error probabilities for heroin ($\beta = 0.076$) and methamphetamine ($\beta = 0.18$) reflect greater volatility in these series, resulting in wider confidence intervals. In both cases, the probability of failing to detect a true *increase* in mortality exceeded the probability of missing a true decrease.

4.4. Alternative Explanations:

One alternative hypothesis is that the proportion of illicit drug doses containing fentanyl declined rather than that fentanyl potency decreased. To the best of the author's knowledge, no recent literature supports this hypothesis.

Although reduced fentanyl potency is the most plausible explanation for the observed mortality decline, the underlying cause of this potency reduction remains uncertain. DEA attributes declining purity to enforcement-driven constraints on precursor availability. Other explanations—including reductions in potency by suppliers for economic or political reasons—should not be excluded.

4.5. Policy Implications:

Supply-side interventions have contributed to reduced fentanyl potency and merit continued support. However, historical experience indicates that supply control has limited long-term effectiveness, as illicit markets adapt through shifts in precursor sourcing, production sites, trafficking routes, or adoption of more potent synthetic opioids. Recent increases in deaths involving nitazenes (Bonner, 2024) and carfentanil (Tanz et al., 2024) highlight this risk.

While this study does not support the hypothesis that infrastructure improvements drove the rapid, fentanyl-specific mortality decline observed in 2024, infrastructure investments remain essential for long-term improvement in the opioid epidemic and should not be viewed as inconsistent with these findings.

Enhanced national drug mortality monitoring and drug-supply reporting are needed. Routine disaggregation of overdose deaths by fentanyl co-involvement would clarify the drivers of emerging trends, and expanded tracking of high-potency synthetic opioids (e.g., nitazenes, carfentanil) is critical given the potential for rapid market substitution. DEA data should be released more frequently and with greater granularity.

4.6. Limitations:

The 2024 data were provisional, although CDC validation studies suggest that provisional totals reliably reflect final patterns (Ahmad et al., 2025). Death certificate data may

underdetect specific substances, though this is unlikely to differentially affect fentanyl-positive versus fentanyl-negative classification.

5. Conclusion:

The large decrease in 2024 overdose mortality occurred primarily among deaths involving fentanyl. Mortality from overdoses of fentanyl-negative drugs did not show a similar decline. Even the modest declines in deaths from fentanyl-negative prescription opioids and heroin reflect longer-term trends rather than an acute decrease. The decrease in overdose deaths appears dependent on a less lethal supply of illicit drugs. Given past experience, this victory may be very short-lived. Reducing future mortality will require both continued supply reduction and strengthened public health infrastructure capable of responding to an evolving and volatile drug market.

References:

[1] Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics, 2025. (Accessed July 26, 2025, at https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm).

[2] Anderer S. US drug overdose deaths dropped nearly 27% last year. JAMA 2025;334:107. https://doi.org/10.1001/jama.2025.779.

[3] Bonner L. Overdose deaths involving nitazenes seem to be on the rise. American Pharmacists Association, 2024. (Accessed July 26, 2025, at https://www.pharmacist.com/Blogs/CEO-Blog/overdose-deaths-involving-nitazenes-seem-to-be-on-the-rise).

[4] Centers for Disease Control and Prevention. CDC reports nearly 24% decline in US drug overdose deaths. 2025a. (Accessed July 26, 2025, at https://www.cdc.gov/media/releases/2025/s0225-overdose-death-decline.html).

[5] Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System, provisional mortality on CDC WONDER online database. (Accessed July 26, 2025b, at http://wonder.cdc.gov/mcd-icd10-provisional.html).

[6] Dasgupta N, Miller C, Sibley A. Peak OD phenotypes. Opioid Data Lab, 2025. (Accessed July 26, 2025, at https://opioiddatalab.ghost.io/peak-od-phenotypes/).

[7] Drug Enforcement Administration. DEA's third annual National Family Summit on Fentanyl highlights progress in fight to save lives. 2024. (Accessed July 26, 2025,

at https://www.dea.gov/press-releases/2024/11/15/deas-third-annual-national-family-summit-fentanyl-highlights-progress).

[8] Drug Enforcement Administration. One Pill Can Kill. 2025. (Accessed July 26, 2025, at https://www.dea.gov/onepill).

[9] Fischer B, Hall W, Jutras-Aswad D, Le Foll B. Considering possible drivers of the recent decrease in drug overdose deaths in Canada. Lancet Reg Health Am 2025;47:101141. https://doi.org/10.1016/j.lana.2025.101141.

[10] Milgram A. We targeted drug cartels to stop fentanyl. Now, overdose deaths are dropping. USA Today, 2024. (Accessed July 26, 2025, at https://www.usatoday.com/story/opinion/2024/11/26/dea-drug-deaths-fentanyl-mexican-cartels/75487168007/).

[11] National Center for Health Statistics. US overdose deaths decrease almost 27% in 2024. 2025. (Accessed July 26, 2025, at https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2025/20250514.htm).

[12] Tanz LJ, Stewart A, Gladden RM, Ko JY, Owens L, O'Donnell J. Detection of illegally manufactured fentanyls and carfentanil in drug overdose deaths—United States, 2021–2024. MMWR Morb Mortal Wkly Rep 2024;73:1099–105. https://doi.org/10.15585/mmwr.mm7348a2.

[13] World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva: World Health Organization; 1992.